CN101115749B - 氨基嘧啶化合物和使用方法 - Google Patents

氨基嘧啶化合物和使用方法 Download PDF

Info

Publication number
CN101115749B
CN101115749B CN2005800479087A CN200580047908A CN101115749B CN 101115749 B CN101115749 B CN 101115749B CN 2005800479087 A CN2005800479087 A CN 2005800479087A CN 200580047908 A CN200580047908 A CN 200580047908A CN 101115749 B CN101115749 B CN 101115749B
Authority
CN
China
Prior art keywords
ethyl
pyrimidin
ylamino
dimethyl
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2005800479087A
Other languages
English (en)
Chinese (zh)
Other versions
CN101115749A (zh
Inventor
A·L·史密斯
P·E·布伦南
F·F·德莫林
刘钢
N·A·帕拉斯
D·M·雷茨
E·瑞恩博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN101115749A publication Critical patent/CN101115749A/zh
Application granted granted Critical
Publication of CN101115749B publication Critical patent/CN101115749B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN2005800479087A 2004-12-17 2005-12-16 氨基嘧啶化合物和使用方法 Expired - Lifetime CN101115749B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63660404P 2004-12-17 2004-12-17
US60/636,604 2004-12-17
PCT/US2005/045863 WO2006066172A1 (en) 2004-12-17 2005-12-16 Aminopyrimidine compounds and methods of use

Publications (2)

Publication Number Publication Date
CN101115749A CN101115749A (zh) 2008-01-30
CN101115749B true CN101115749B (zh) 2011-06-22

Family

ID=36588221

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800479087A Expired - Lifetime CN101115749B (zh) 2004-12-17 2005-12-16 氨基嘧啶化合物和使用方法

Country Status (9)

Country Link
US (2) US7786132B2 (https=)
EP (1) EP1831207B1 (https=)
JP (1) JP4932735B2 (https=)
CN (1) CN101115749B (https=)
AU (1) AU2005316312B2 (https=)
CA (1) CA2590939C (https=)
ES (1) ES2397362T3 (https=)
MX (1) MX2007007032A (https=)
WO (1) WO2006066172A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
TW200800201A (en) * 2005-11-18 2008-01-01 Lilly Co Eli Pyrimidinyl benzothiophene compounds
AU2006331656B2 (en) * 2005-12-22 2012-08-09 Icagen, Inc. Calcium channel antagonists
EP2474546A1 (en) 2006-01-23 2012-07-11 Vertex Pharmaceuticals Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007120760A2 (en) * 2006-04-13 2007-10-25 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007139795A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
WO2007139816A2 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
CN100422331C (zh) * 2006-06-28 2008-10-01 南京农业大学 一个簇毛麦丝氨酸/苏氨酸激酶基因及其所编码的蛋白质
AU2007275221A1 (en) * 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
DK2125794T3 (da) * 2006-12-21 2011-01-24 Lilly Co Eli Imidazolidinonylaminopyrimidin-forbindelser til behandling af cancer
ES2349169T3 (es) * 2006-12-21 2010-12-28 ELI LILLY & COMPANY Compuestos de imidazolidinonil aminopirimidina para el tratamiento del cáncer.
WO2008093677A1 (ja) * 2007-01-29 2008-08-07 Santen Pharmaceutical Co., Ltd. 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
CN101679396B (zh) * 2007-05-16 2012-06-06 伊莱利利公司 三唑基氨基嘧啶化合物
US8063035B2 (en) 2007-05-16 2011-11-22 Eli Lilly And Company Triazolyl aminopyrimidine compounds
KR20100092473A (ko) * 2007-11-01 2010-08-20 액테리온 파마슈티칼 리미티드 신규한 피리미딘 유도체
EP2583556B1 (de) * 2008-07-17 2016-01-20 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US20120015399A1 (en) * 2009-02-06 2012-01-19 National University Corporation Hokkaido University Fluorescent solvatochromic pigment
US20120263646A1 (en) * 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
JP2013147428A (ja) * 2010-04-27 2013-08-01 Dainippon Sumitomo Pharma Co Ltd 新規２−ヘテロアリール単環ピリミジン誘導体
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2013119895A1 (en) 2012-02-08 2013-08-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
CN104860900A (zh) * 2014-02-25 2015-08-26 中国药科大学 噻唑类化合物、其制备方法及其在制药中的用途
CN105884711A (zh) * 2014-12-16 2016-08-24 中国药科大学 噻唑类化合物、其制备方法及其在制药中的用途
PT3319939T (pt) * 2015-07-08 2025-03-05 Cv6 Therapeutics Ni Ltd Inibidores de desoxiuridina-trifosfatase contendo hidantoína
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
CA3006077A1 (en) 2015-12-17 2017-06-22 Arqule, Inc. Methods for preparing polymorphs of substituted 5,6-dihydrobenzo[h]quinazolin-2-amine
PT3494119T (pt) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compostos e composições e seus usos
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN112125879A (zh) * 2020-09-29 2020-12-25 浙江永太科技股份有限公司 一种卡格列净中间体2-(4-氟苯基)噻吩的制备方法
CN114133337A (zh) * 2020-12-14 2022-03-04 成都泰蓉生物科技有限公司 一种2-取代的赖氨酸的制备方法
KR20230155452A (ko) * 2021-03-09 2023-11-10 바스프 에스이 트리시클릭 살충 화합물
US20230263783A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合
CN117050051A (zh) * 2023-08-14 2023-11-14 上海药坦药物研究开发有限公司 一种2-溴-1-（5-碘噻吩-2-基）-乙酮的纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093249A1 (de) * 2002-05-03 2003-11-13 Schering Aktiengesellschaft Thiazolidinone und ihre verwendung als polo like kinase inhibitoren

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2087056T3 (es) 1986-01-13 1996-07-16 American Cyanamid Co 2-pirimidinaminas sustituidas en las posiciones 4, 5 y 6.
DE4025891A1 (de) 1990-08-16 1992-02-20 Bayer Ag Pyrimidyl-substituierte acrylsaeureester
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO1999065897A1 (en) * 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CA2358047A1 (en) 1998-12-24 2000-07-06 Francis A. Volz Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
AU9502601A (en) 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3
MXPA03010961A (es) * 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
CN100500663C (zh) * 2001-09-28 2009-06-17 西克拉塞尔有限公司 作为抗增殖化合物的n-(4-(4-甲基噻唑-5-基)嘧啶-2-基)-n-苯胺
US7361665B2 (en) * 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
AU2003284399A1 (en) * 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
AR044519A1 (es) * 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093249A1 (de) * 2002-05-03 2003-11-13 Schering Aktiengesellschaft Thiazolidinone und ihre verwendung als polo like kinase inhibitoren

Also Published As

Publication number Publication date
WO2006066172A1 (en) 2006-06-22
JP4932735B2 (ja) 2012-05-16
JP2008524248A (ja) 2008-07-10
EP1831207A1 (en) 2007-09-12
ES2397362T3 (es) 2013-03-06
EP1831207A4 (en) 2010-09-15
CA2590939A1 (en) 2006-06-22
AU2005316312B2 (en) 2009-10-22
AU2005316312A1 (en) 2006-06-22
US7786132B2 (en) 2010-08-31
MX2007007032A (es) 2007-07-04
EP1831207B1 (en) 2012-11-14
US20100010014A1 (en) 2010-01-14
CA2590939C (en) 2011-10-18
US20070185133A1 (en) 2007-08-09
US7858785B2 (en) 2010-12-28
CN101115749A (zh) 2008-01-30

Similar Documents

Publication Publication Date Title
CN101115749B (zh) 氨基嘧啶化合物和使用方法
CN102781942B (zh) 用作食欲肽受体调节剂的二取代八氢吡咯并[3,4-c]吡咯
EP3468971B1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
CN100357278C (zh) 作为激酶抑制剂的取代的三唑二胺衍生物
KR101332975B1 (ko) 오로라 키나제 조절제 및 사용 방법
CN101437816B (zh) 作为葡萄糖激酶活性剂的2-氨基吡啶类似物
EP1633740B1 (en) 5-(acylamino)indazole derivatives as kinase inhibitors
CA2593450A1 (en) Indole derivatives for treating viral infections
WO2010038081A2 (en) Heterocyclic derivatives and methods of use thereof
CN102365277A (zh) Jun n-末端激酶抑制剂
JP2013536193A (ja) ヘテロアリール類およびその使用
AU2005228899A1 (en) Substituted thiophene derivatives as anti-cancer agents
MX2007014784A (es) Derivados de benzoamida de heteroarilo para utilizarse como activadores glk en el tratamiento de diabetes.
KR20050071471A (ko) 티오펜 화합물
KR20080059451A (ko) 암 및 염증성 질환 치료를 위한 ｉｋｋ-베타 억제제로서의[4-벤조[ｂ]티오펜-2-일)피리미딘-2-일]-아민 유도체
KR20120089648A (ko) 결핵 억제제로서의 피리미딘 화합물
CN101405282B (zh) 极光激酶调节剂和使用方法
ES2349169T3 (es) Compuestos de imidazolidinonil aminopirimidina para el tratamiento del cáncer.
JP2009539770A (ja) Ｐｌｋに対する活性を有するベンゾイミダゾール置換チオフェン誘導体
HK40007202B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40007202A (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: A.L. Smith

Inventor after: Paras Nick A.

Inventor after: F.F. de Morin

Inventor after: Liu Gang

Inventor after: N.A. Pallas

Inventor after: Retz Daniel M.

Inventor after: E. Ryan Bo

Inventor before: A.L. Smith

Inventor before: Paras Nick A.

Inventor before: F.F. de Morin

Inventor before: Liu Gang

Inventor before: N.A. Pallas

Inventor before: Retz Daniel M.

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: A L SMITH P E BRENNAN F F DEMOULIN LIU GANG N A PALLAS D M REZ TO: A L SMITH P E BRENNAN F F DEMOULIN LIU GANG N A PALLAS D M REZ E RUIENBO

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20110622